WASSERBILLIG, Luxembourg — The pjur Group has reported a clinical trial carried out by the University of Melbourne and Australia's Royal Women’s Hospital indicated pjur’s silicone-based lubricant provided more relief to breast cancer patients experiencing discomfort during sex over another brand’s water-based lubricant.
According to the brand, vaginal dryness is a common side effect of cancer therapies. 38 female breast cancer patients took part in the trial. 90 percent of the women experienced significant distress during sexual intercourse at the beginning of the trial. The participants used each of the personal lubricants for four weeks.
“The efficacy of the lubricant was an important factor when evaluating the results,” a pjur spokesperson said. “In other words, whether and to what extent the respective personal lubricant helped to reduce discomfort. Acceptability was also evaluated for each product to determine whether the participants preferred one of the products and/or would continue to use them in future.”
For more information, visit pjurLove.com.
